The White House's proposed FY 2015 budget gives an additional 1% to the FDA.
The regulator is allowing generic makers room on the OTC contraceptive shelf.
Critics say the FDA is not doing enough to ensure generics quality and that communications between industry and the regulator need to improve.
The drugmaker says the voluntary measure was out of an abundance of caution.
The regulator kicked off a $20-million generics testing project in September.
The drugmakers admitted no wrongdoing, but are paying the state $300,000 over an agreement not to challenge generics filings.
The drugmaker, hitherto known for its generic expertise, says the purchase could mean that half its future revenue will come from branded, specialty drugs.
Innovator companies want the FDA to adopt separate names for biosimilars. Manufacturing changes aren't drastic enough to make it necessary, experts argued at an FTC workshop.
FDA found workers were manipulating test data.
Purdue Pharma says it will appeal.
The generics giant is splitting the business into four separate units with a newly appointed leader running each.
Generics accounted for almost 75% of dispensed drugs in 2012, according to CMS researchers.
The company's guidance aligns with expectations that 2014 will be a nail-biter.
The generics maker says an adalimumab biosimilar would anchor its immunology portfolio.
The company released two financial scenarios. The key is generic Copaxone.
A study points out barriers to e-prescribing pharma products and shows how doctors rate various EHRs.
ProPublica's deep-dive into Medicare brand-prescribing habits show brands make a dent in Medicare's budget.
The catch is the difference between sales and revenues. Generics will continue to be a force, and small-audience drugs will become increasingly important.
The proposed change would allow generics makers to update labels even if branded drugmakers do not, possibly opening up generics to new liability issues.
Researchers say it's not just payers supporting the switch, and all ages appear to be brand agnostic.
The governor says it is too early to legislate on drugs the FDA is still deliberating over.
The agency says the copycat antidepressant failed to meet bioequivalency requirements.
The generics giant said it will lay off about 5,000 employees as it braces for the expiry of one of its specialty brands.
The generics maker says it may take five years for its iteration of the GSK asthma/COPD brand to hit the market.
The regulator says serial filers and time restraints are draining resources and staff.
The advisory panel endorsed the treatment with an 11-2 vote.
FDA draft guidance for generic Advair hits GSK's stock; US looks into GSK's China conduct; Roche invests in cancer and hep. B research; Biogen inks a Parkinson's partnership; Forest names former B&L chief as CEO
Biogen extend Isis relationship for six years and $100M; HHS readies healthcare reform TV push; Medivir ends hep. B clinical trial; FDA approves Celgene cancer drug; Baxter seeks Enbrel biosimilar
FDA is concerned state biosimilar legislation could make consumers uneasy about the category, J&J hands $75 million milestone payment for ibrutinib, Consumer Reports gets into drug apps
The positive way to frame the companies' quarterly results: "less bad," as generics continued to plague their balance sheets.